Ashland closed fiscal 2026 with a quarter that looks better operationally than it does against Wall Street's bar. Adjusted earnings of $1.12 per share rose 3.7% from a year ago but missed the $1.30 consensus by 13.8%. Revenue of $498.0 million grew 4.2%, just short of the $500.66 million estimate, a 0.5% miss. The top line was essentially on target. The bottom line was not, and the reason is clear: Ashland's two premium franchises are running at record profitability, while a single troubled plant and higher corporate costs absorbed most of those gains. That is the central tension heading into fiscal 2027.

The quality of the quarter deserves a closer look on both the GAAP and adjusted sides. On a GAAP basis, Ashland swung to a continuing-operations loss of $0.36 per share from income of $0.73 a year earlier. Higher restructuring charges and a cumulative translation adjustment tied to liquidating its Argentine entity drove that swing. Adjusted EBITDA rose only 2% to $121 million, and the consolidated margin slipped to 24.3% from 24.9%, even with volumes up 3% and pricing up 2%. Specialty Additives explains most of the gap. Segment EBITDA fell 31% to $20 million on lower Hopewell productivity and unfavorable absorption, while adjusted unallocated expense rose to $18 million from $13 million on incentive and stock compensation. For the full year, adjusted EPS of $3.31 came in slightly below the prior year's $3.38, and adjusted EBITDA of $385 million landed at the bottom of a guidance range that had already been trimmed.

Beneath that, the operating trajectory improved meaningfully through the year. Adjusted EBITDA climbed sequentially from $98 million in the fiscal second quarter to $109 million in the third and $121 million in the fourth. Management cited roughly 400 basis points of margin recovery over that span. Pricing moved from a 2% decline in Q2 to a 2% gain in Q4, a sign that cost recovery is working. Life Sciences posted a record 35.6% EBITDA margin, up from 33% in Q3, as pharma logged a sixth straight quarter of volume growth. Personal Care sales growth accelerated from 3% to 5% to 8% across the last three quarters, and management is now targeting a mid-30s margin there. Not every trend improved. Life Sciences sales growth slowed from 11% in Q3 to 4%, and nutrition was soft. Specialty Additives sales were flat, as share gains in coatings and performance specialties were offset by weak energy and resources demand, which management tied to an Iran-related impact of about $30 million, and by deliberately reduced construction volumes.

Fiscal 2027 guidance calls for sales of $1.905-$1.975 billion and adjusted EBITDA of $405-$435 million. That implies EBITDA growth from fiscal 2026's $385 million, but the outlook appears to sit roughly in line with expectations rather than ahead of them. It also leans heavily on self-help. Management expects Hopewell output to rise about 25% in fiscal 2027 and to lap roughly $20 million of Calvert City and weather disruptions in the first half. Even so, net productivity benefits are only about $10 million, and roughly $5 million of Hopewell under-absorption carries into Q1. The innovation pipeline gives bulls more to work with:

• The combined Globalize and Innovate target rises to $65 million, after about $52 million in fiscal 2026 beat a $35 million goal.
• The Permexa launch for oral biologics and GLP-1 applications has more than 60 active customer engagements.
• A multi-year U.S. energy-storage contract in Intermediates begins ramping this year.

Bears have legitimate ammunition on cash. Capex steps up to as much as $140 million from roughly $90 million, and free cash flow conversion is guided above 40%, versus 61% in Q4. A stronger dollar is expected to cost $7-$10 million of EBITDA. A €500 million bond maturing in January 2028 also needs to be addressed, though net leverage of 2.3x and $976 million of liquidity provide flexibility. Questions about a possible sale process following the Ancora settlement went unanswered.

Investor sentiment improved from essentially neutral at 0.0094 to a mildly positive 0.1128. That is a meaningful shift in direction but not enthusiasm. The stock has gone nowhere since the last report: at $73.02, it is unchanged from the $73.00 open after the July release. It still sits 14.4% above its 200-day moving average of $63.83, so the market has held earlier gains while waiting for evidence. With AVWAP readings positive and price and momentum trends neutral, the technical picture matches that holding pattern.

The bottom line is that Ashland delivered a genuine operating recovery in its best businesses and issued a growth outlook. However, it again missed on earnings because Hopewell and corporate costs absorbed the upside. Fiscal 2027 depends less on demand than on execution at the plant level. Until Specialty Additives margins recover and cash conversion stops getting diluted by capex, record segment margins alone are unlikely to close the credibility gap the EPS miss exposed.